Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

1481204

USP

Oxaliplatin

Name: Oxaliplatin
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Faça loginpara ver os preços organizacionais e de contrato

Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):

C₈H₁₄N₂O₄Pt

Número CAS:

61825-94-3

Peso molecular:

397.29

Número MDL:

MFCD00866327

Código UNSPSC:

41116107

ID de substância PubChem:

329750629

NACRES:

NA.24

Produtos recomendados

Slide 1 of 10

1 of 10

Supelco

PHR1528

Oxaliplatin

Sigma-Aldrich

O9512

Oxaliplatin

Y0000272

Oxaliplatin impurity B

Sigma-Aldrich

F6627

5-Fluorouracil

Supelco

PHR2717

Irinotecan Hydrochloride

Supelco

PHR1803

Paclitaxel

Supelco

PHR2545

Oxaliplatin Related Compound A

Sigma-Aldrich

I1406

Irinotecan hydrochloride

Supelco

PHR1624

Cisplatin

Supelco

PHR1227

Fluorouracil

grau

pharmaceutical primary standard

família API

oxaliplatin

fabricante/nome comercial

USP

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

chave InChI

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Oxaliplatin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Oxaliplatin Injection
Oxaliplatin for Injection

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto

Descrição

Preços

1481215

1481237

1481248

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

PHR2545

Pictogramas

GHS08,GHS05

Palavra indicadora

Danger

Frases de perigo

H317,H318,H334,H341,H351,H360FD,H362,H372

Declarações de precaução

P260 - P263 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Classificações de perigo

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.

L B J van Iersel et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(11), 1557-1563 (2014-08-16)

To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose. Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and

Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping.

Maire F Osborn et al.

ACS chemical biology, 9(10), 2404-2411 (2014-07-24)

With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids.

Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

Jennifer R Deuis et al.

Neuro-oncology, 16(10), 1324-1332 (2014-04-10)

Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.

Hirofumi Yasui et al.

Journal of cancer research and clinical oncology, 141(1), 153-160 (2014-08-12)

The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at

Polymeric micelles loaded with platinum anticancer drugs target preangiogenic micrometastatic niches associated with inflammation.

Hailiang Wu et al.

Journal of controlled release : official journal of the Controlled Release Society, 189, 1-10 (2014-06-24)

Nanocarriers have been used for specific delivery of therapeutic agents to solid tumors based on the enhanced permeability and retention in cancerous tissues. Despite metastasis is the main reason of cancer-related death and a priority for nanocarrier-based therapies, the targeting

Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica

Documentos Principais

Oxaliplatin

United States Pharmacopeia (USP) Reference Standard

About This Item

Produtos recomendados

Propriedades

grau

família API

fabricante/nome comercial

aplicação(ões)

Formato

temperatura de armazenamento

cadeia de caracteres SMILES

InChI

chave InChI

Descrição

Descrição geral

Aplicação

Nota de análise

Outras notas

Produtos relacionados

produto relacionado

Informações de segurança

Pictogramas

Palavra indicadora

Frases de perigo

Declarações de precaução

Classificações de perigo

Código de classe de armazenamento

Classe de risco de água (WGK)

Ponto de fulgor (°F)

Ponto de fulgor (°C)

Documentação

Certificados de análise (COA)

Já possui este produto?

Artigos revisados por pares

Assistência Técnica